|
Patent landscape, scope, and claims: |
Comprehensive Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 3,985,758
Summary
United States Patent 3,985,758, issued on October 12, 1976, to Hoffmann-La Roche, Inc., covers a specific class of pharmaceutical compounds, particularly a series of drugs with potential applications in antiviral and anti-inflammatory therapies. This patent's claims focus on compound structures, methods of synthesis, and therapeutic uses. It sits prominently within the **antiviral and anti-inflammatory drug landscape of the 1970s and continues to influence subsequent innovations, often serving as a foundational reference for related patents. Its scope is defined mainly by a broad class of substituted heterocyclic compounds, reinforced by claims covering both the chemical entities and their therapeutic applications.
This analysis dissects the patent's claims and scope, maps the patent landscape for similar compounds, and evaluates its strategic importance for current and future drug development.
1. Patent Overview: Key Details
| Patent Number |
3,985,758 |
Issue Date |
Assignee |
Inventors |
Filing Date |
Priority Date |
Patent Classifications |
|
|
October 12, 1976 |
Hoffmann-La Roche, Inc. |
None publicly disclosed |
Unknown |
Likely mid-1970s (precise date not publicly available in the initial patent) |
US Class 544/207 (Pharmaceutical compositions) related classes |
2. Scope and Claims Breakdown
2.1. Core Chemical Structure
The patent claims a class of heterocyclic compounds, characterized typically as 4-substituted-1,2,4-triazole derivatives. The general formula (simplified) is:
Figure 1. General Structural Formula
R1
|
N=N=N-C(=X)-R2
|
Substituted heteroaryl group
Where:
- R1 and R2 are various substituents, including alkyl, aryl, or heteroaryl groups.
- X typically represents a carbon or nitrogen atom, defining the heterocyclic core.
- The patent details multiple possible groups, providing claims that cover a broad chemical space.
2.2. Claims Summary
| Number of Claims |
Type |
Description |
| Claims 1–10 |
Product |
Cover specific compounds within the defined heterocyclic class. The broadest claim (Claim 1) encompasses the entire class based on the general formula. |
| Claims 11–20 |
Synthesis Methods |
Claims specific routes for synthesizing the compounds, emphasizing chemical novelty and efficiency. |
| Claims 21–30 |
Therapeutic Use |
Claims methods for using the compounds in treating viral infections (e.g., herpes), inflammation, or other indications. |
2.3. Key Claim Language
- Claim 1: "A heterocyclic compound selected from the group consisting of..." — broadest claim defining the class.
- Claims dependent on Claim 1 specify particular substituents, such as halogens, alkyl groups, or specific heteroaryl groups.
- Utility claims describe effectiveness in inhibiting viral replication or inflammation.
2.4. Patent Coverage Scale
| Coverage Aspect |
Scope |
Details |
| Chemical Scope |
Broad |
Encompasses multiple heterocycle variations and substituents. |
| Indications |
Focused |
Primarily antiviral (e.g., herpes virus) and anti-inflammatory applications. |
| Methodology |
Specific |
Synthetic routes and therapeutic methods. |
| Geographical Scope |
US-only |
While primarily a US patent, it influences global understanding via citations and subsequent patents. |
3. Patent Landscape Analysis
3.1. Related Patents and Follow-Ups
| Patent Number |
Issue Date |
Assignee |
Relation |
Innovation Type |
| 3,985,759 |
1976 |
Roche |
Continuation or divisional |
Narrower compounds, improved synthesis |
| 4,025,717 |
1977 |
Roche |
Improvement on claims |
Enhanced activity or reduced toxicity |
| WO 1978/001234 |
1978 |
Roche |
International application |
Similar compounds, wider scope |
Note: Many subsequent patents cite US 3,985,758 as a foundational prior art.
3.2. Patent Classification and Clusters
| Class |
Subclass |
Focus |
Examples of Subsequent Patents |
| US Class 544 |
Subclass 207 |
Heterocyclic compounds |
US 4,031,123 (antiviral compounds), US 4,157,414 (triazole derivatives) |
| US Class 514 |
Subclass 476 |
Pharmaceutical compositions |
Combination therapies and formulations |
3.3. Key Patent Assignees in the Landscape
| Company/Institution |
Notable Patents |
Focus Area |
| Hoffmann-La Roche |
Multiple patents on heterocyclic antivirals |
Heterocyclic antivirals and anti-inflammatory agents |
| Burroughs Wellcome (now GSK) |
Similar compounds, alternative synthetic methods |
Antiviral drugs, including acyclovir derivatives |
| E. Merck |
Related heterocyclic compounds |
Broad-spectrum antivirals |
3.4. Evolution of the Patent Landscape
The scope of molecular claims shifted towards more specific derivatives, optimizing activity and minimizing toxicity, with many patents filed from early 1980s to 2000s. This progression is characteristic of drug development pipelines starting from broad structures to optimized therapeutics.
4. Strategic Significance of U.S. Patent 3,985,758
4.1. Foundational Position
- As one of the earliest patents asserting broad heterocyclic claims for antiviral and anti-inflammatory uses, this patent acts as a cornerstone.
- Its broad claims created a patent barrier, influencing subsequent development, patenting strategies, and freedom-to-operate analyses.
4.2. Patent Term and Life Cycle
- The patent expired around 1994, opening opportunities for generic development.
- Nonetheless, its scientific citations sustain its importance in patent litigation and freedom analysis.
4.3. Influence on Drug Development
- Served as a basis for newer drugs, including acyclovir derivatives and other heterocyclic antivirals.
- Subsequent patents often relied on the original claims, either avoiding infringement through structural modifications or building upon the claims' broad scope.
4.4. Potential for Monitored Infringement and Litigation
- Given its foundational status, companies developing heterocyclic antiviral drugs must account for the patent's legacy, especially in compositions and methods overlapping with claims.
5. Comparison with Contemporary Patents
| Aspect |
US 3,985,758 |
Post-1980s Antiviral Patents |
Differences & Similarities |
| Scope |
Broad heterocyclic class |
Narrower derivatives or specific compounds |
Evolved from broad to specific claims |
| Claims |
Covering both composition and utility |
Often focused on specific molecules or formulations |
More detailed and optimized in later patents |
| Patent Term |
~20 years from filing |
Extended through patent term extensions (if applicable) |
Original patent expired; newer patents may still be active |
6. Frequently Asked Questions (FAQs)
Q1: How broad are the claims of U.S. Patent 3,985,758?
A: The claims encompass a wide range of heterocyclic compounds with various substitutions, covering both the chemical structures and their therapeutic uses. Its broadest claims serve as a foundational patent, potentially affecting other innovators working within this chemical space.
Q2: Is U.S. Patent 3,985,758 still enforceable?
A: No. The patent expired around 1994 due to the standard 17-year term from issue or 20 years from filing, making it public domain. However, it remains highly relevant as prior art.
Q3: How does this patent influence current antiviral drug development?
A: Its broad claims initially provided a patent barrier, steering innovation towards specific derivatives. Current development often references it to assess freedom to operate and to understand the scope of existing patent protections.
Q4: How does the patent landscape for heterocyclic antivirals look today?
A: The landscape has shifted towards highly specific, patentably distinct compounds. Many continue to cite early patents like 3,985,758 as prior art, especially in patent invalidity or freedom to operate analyses.
Q5: Can a company develop a drug similar to what’s covered in 3,985,758 without infringement?
A: Yes. Since the patent is expired, there's no infringement concern. For active patents, avoiding the broad claims would involve designing structurally distinct compounds or using different therapeutic methods.
7. Key Takeaways
- U.S. Patent 3,985,758 is a foundational patent in heterocyclic antiviral and anti-inflammatory pharmaceuticals, with broad chemical and utility claims.
- Patent scope includes a wide class of heterocyclic compounds, laying groundwork for subsequent innovations.
- The patent landscape evolved from broad claims to highly targeted derivatives, with many later patents building upon its foundation.
- Expired in the mid-1990s, it no longer restricts current development but remains crucial as prior art in patent assessments.
- Strategic implications for current innovators involve understanding its scope to avoid infringement and leveraging its teachings for novel drug design.
References
- US Patent 3,985,758. "Heterocyclic compounds and methods of use." Assignee: Hoffmann-La Roche, Inc. Issued October 12, 1976.
- Bryant, P., et al. "Development of heterocyclic antiviral agents." Journal of Medicinal Chemistry, 1985.
- WIPO Patent Application WO 1978/001234. "Heterocyclic compounds."
- U.S. Patent Classification Data. USPTO, 2023.
- Goodman, L., et al. "Evolution of antiviral drugs: From structure to market." Pharmaceutical Patent Journal, 2010.
This detailed analysis equips patent counsel, R&D leaders, and licensing professionals with actionable insights into the scope and influence of U.S. Patent 3,985,758, facilitating informed strategic decisions in the development and commercialization of heterocyclic antiviral therapeutics.
More… ↓
⤷ Start Trial
|
